Leveraging the LION Nanoformulation Technology to Unlock saRNA for the Development of Personalized Cancer Vaccines
4:30 pm - Thursday 3rd December 2026
- Showcasing the potential of LION for improved safety, stability and precise extrahepatic delivery of cancer immunotherapies
- Uncovering the superior T-cell response achieved from saRNA/LION vaccines
- Highlighting how LION delivery can transform manufacture, cost and logistics including quick, LNP-free, bedside preparation of personalized cancer vaccines for patients
